Do Not Miss Acute Diffuse Panbronchiolitis for Tree-in-Bud: Case Series of a Rare Lung Disease
Abstract
:1. Introduction
2. Case Presentations
2.1. Case 1
2.2. Case 2
2.3. Case 3
2.4. Case 4
3. Discussion
- An adequate medical history is the key to proper diagnosis and therapy. Therefore, a thorough history must be taken in a calm, trust-building environment to obtain honest answers to sensitive questions regarding drug use.
- Early CT scans should be taken to identify BD in adolescents with potential inhalation hazards and progressive pulmonary symptoms.
- Broad infectious work-up including sputum, serum (blood cultures, titers, and PCR), and BAL analysis should be performed.
- Lung biopsy (video-assisted thoracic surgery or trans-bronchial biopsy) should be performed if clinically feasible for histological diagnosis and if uncertain about diagnosis.
- Initial urine and blood specimens should be taken for toxicological analysis (e.g., immunoassays, gas, or liquid-chromatography mass spectrometry). Consider that novel drugs may not be included in standard diagnostic panels.
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Florin, T.A.; Plint, A.C.; Zorc, J.J. Viral bronchiolitis. Lancet 2017, 389, 211–224. [Google Scholar] [CrossRef]
- Ryu, J.H.; Myers, J.L.; Swensen, S.J. Bronchiolar disorders. Am. J. Respir. Crit. Care Med. 2003, 168, 1277–1292. [Google Scholar] [CrossRef]
- Winningham, P.J.; Martínez-Jiménez, S.; Rosado-de-Christenson, M.L.; Betancourt, S.L.; Restrepo, C.S.; Eraso, A. Bronchiolitis: A Practical Approach for the General Radiologist. Radiographics 2017, 37, 777–794. [Google Scholar] [CrossRef] [Green Version]
- Poletti, V.; Chilosi, M.; Casoni, G.; Colby, T.V. Diffuse panbronchiolitis. Sarcoidosis Vasc Diffus. Lung Dis. 2004, 21, 94–104. [Google Scholar] [CrossRef]
- Poletti, V.; Casoni, G.; Chilosi, M.; Zompatori, M. Diffuse panbronchiolitis. Eur. Respir. J. 2006, 28, 862–871. [Google Scholar] [CrossRef] [PubMed]
- Aslan, A.T.; Ozcelik, U.; Talim, B.; Haliloglu, M.; Dogru, D.; Dalgic, F.; Kiper, N. Childhood diffuse panbronchiolitis: A case report. Pediatric Pulmonol. 2005, 40, 354–357. [Google Scholar] [CrossRef] [PubMed]
- Layden, J.E.; Ghinai, I.; Pray, I.; Kimball, A.; Layer, M.; Tenforde, M.W.; Navon, L.; Hoots, B.; Salvatore, P.; Elderbrook, M.; et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin—Final Report. N. Engl. J. Med. 2020, 382, 903–916. [Google Scholar] [CrossRef]
- Blount, B.C.; Karwowski, M.P.; Shields, P.G.; Morel-Espinosa, M.; Valentin-Blasini, L.; Gardner, M.; Braselton, M.; Brosius, C.R.; Caron, K.T.; Chambers, D.; et al. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N. Engl. J. Med. 2020, 382, 697–705. [Google Scholar] [CrossRef]
- Nair, N.; Hurley, M.; Gates, S.; Davies, P.; Chen, I.L.; Todd, I.; Fairclough, L.; Bush, A.; Bhatt, J.M. Life-threatening hypersensitivity pneumonitis secondary to e-cigarettes. Arch. Dis. Child. 2019, 105, 1114–1116. [Google Scholar] [CrossRef]
- Marliere, C.; De Greef, J.; Gohy, S.; Hoton, D.; Wallemacq, P.; Jacquet, L.M.; Belkhir, L. Fatal e-cigarette or vaping associated lung injury (EVALI): A first case report in Europe. Eur. Respir. J. 2020, 56, 2000077. [Google Scholar] [CrossRef]
- Landman, S.T.; Dhaliwal, I.; Mackenzie, C.A.; Martinu, T.; Steele, A.; Bosma, K.J. Life-threatening bronchiolitis related to electronic cigarette use in a Canadian youth. Can. Med. Assoc. J. 2019, 191, E1321–E1331. [Google Scholar] [CrossRef] [Green Version]
- Suhling, H.; Welte, T.; Fuehner, T. Three Patients with Acute Pulmonary Damage Following the Use of E-Cigarettes—A Case Series. Dtsch. Arztebl. Int. 2020, 117, 177–182. [Google Scholar] [PubMed]
- Casanova, G.S.; Amaro, R.; Soler, N.; Sanchez, M.; Badia, J.R.; Barbera, J.A.; Agustí, A. An imported case of e-cigarette or vaping associated lung injury in Barcelona. Eur. Respir. J. 2020, 55, 1902076. [Google Scholar] [CrossRef] [PubMed]
- Viswam, D.; Trotter, S.; Burge, P.S.; Walters, G.I. Respiratory failure caused by lipoid pneumonia from vaping e-cigarettes. BMJ Case Rep. 2018, 2018, bcr2018224350. [Google Scholar] [CrossRef] [PubMed]
- Werner, A.K.; Koumans, E.H.; Chatham-Stephens, K.; Salvatore, P.P.; Armatas, C.; Byers, P.; Clark, C.R.; Ghinai, I.; Holzbauer, S.M.; Navarette, K.A.; et al. Hospitalizations and Deaths Associated with EVALI. N. Engl. J. Med. 2020, 382, 1589–1598. [Google Scholar] [CrossRef]
- Griese, M. Etiologic Classification of Diffuse Parenchymal (Interstitial) Lung Diseases. J. Clin. Med. 2022, 11, 1747. [Google Scholar] [CrossRef]
- Ebnother, M.; Schoenenberger, R.A.; Perruchoud, A.P.; Soler, M.; Gudat, F.; Dalquen, P. Severe bronchiolitis in acute Mycoplasma pneumoniae infection. Virchows Arch. Int. J. Pathol. 2001, 439, 818–822. [Google Scholar] [CrossRef]
- Berkowitz, E.A.; Henry, T.S.; Veeraraghavan, S.; Staton, G.W.; Gal, A.A. Pulmonary Effects of Synthetic Marijuana: Chest Radiography and CT Findings. Am. J. Roentgenol. 2014, 204, 750–757. [Google Scholar] [CrossRef]
- Alhadi, S.; Tiwari, A.; Vohra, R.; Gerona, R.; Acharya, J.; Bilello, K. High times, low sats: Diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J. Med. Toxicol. Off. J. Am. Coll. Med. Toxicol. 2013, 9, 199–206. [Google Scholar] [CrossRef] [Green Version]
- Selman, M.; Pardo, A.; King, T.E., Jr. Hypersensitivity pneumonitis: Insights in diagnosis and pathobiology. Am. J. Respir. Crit. Care Med. 2012, 186, 314–324. [Google Scholar] [CrossRef] [Green Version]
- Jacob, P., III; Abu Raddaha, A.H.; Dempsey, D.; Havel, C.; Peng, M.; Yu, L.; Benowitz, N.L. Comparison of nicotine and carcinogen exposure with water pipe and cigarette smoking. Cancer Epidemiol. Biomark. Prev. 2013, 22, 765–772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
---|---|---|---|---|
Age (years) | 17 | 16 | 16 | 16 |
Sex | Female | Male | Male | Male |
Presentation | Progressive dry cough, dyspnea and fever, despite 7-day clarithromycin treatment | Progressive cough, hemoptysis and fever | 5-day history of coughing, intermittent slight hemoptysis, orthostatic dizziness, postprandial emesis; no fever | 8-day history of coughing, intermittent hemoptysis |
Days intubated | 3 | 22 | none | 5 |
Past medical history | Uneventful | Uneventful | Uneventful | Uneventful |
Asthma or pulmonary disease | No | No | No | No |
Allergies | None | None | None | Grass pollen |
Vaccinations | Fully vaccinated | Fully vaccinated | Fully vaccinated | Fully vaccinated |
Medication | None | None | None | None |
Drug use | Infrequent use of cigarettes and waterpipe; marijuana was tried 5 days prior to symptom onset; specific products consumed not determinable; other illicit drug use convincingly denied; negative urine toxicology screen | Frequent use of marijuana and waterpipe; specific products consumed not determinable; other illicit drug use convincingly denied | Smokes 10 cigarettes daily for 6 months, regular use of waterpipe and marijuana for several weeks; other illicit drug use denied; positive urine toxicology screen for cannabis | Regular use of tobacco and e-cigarettes, marijuana was smoked 2 and 3 days prior to admission |
Endoscopic findings | Bronchial system shows no anatomic abnormalities. No inflammation of bronchial mucosa, little secretion. No granulomas, no morphologic correlate to a bronchiolitis, no signs of malignancy. | Bronchial system shows no anatomic abnormalities. Mildly inflamed bronchial system with foamy secretion. BAL: neutrophilic/eosinophilic inflammation in bronchi and alveoli. | / | BAL: nonspecific findings with 3% lymphocytes and no infectious pathogens |
Infection | Moderately elevated Mycoplasma pneumoniae serology Negative respiratory PCR for mycoplasma, legionella, mycobacteria, chlamydophila, CMV, and pneumocystis jirovecii. Negative results for HIV, Influenza viruses, Parainfluenza virus, RSV, EBV, CMV, HHV6, HSV, Adenovirus, Enterovirus | Elevated Chlamydophila pneumonia serology Negative respiratory PCR for chlamydophila, mycoplasma, legionella, mycobacteria, pneumocystis jirovecii, HSV, VZV, EBV, CMV, HHV6, Adenovirus, Influenza viruses, RSV, Parainfluenza virus, and Metapneumovirus. Negative serologic tests for aspergillus or candida. | SARS-CoV-2: Negative pharyngeal swab SARS-CoV-2 PCR before admission and on days 0 and 4 after admission. Positive SARS-CoV-2 PCR on days 5 (C(t) > 35), 8 (C(t) = 22), 11 (C(t) = 18.3), 17, 21 (C(t) = 29.1) and 59. Negative SARS-CoV-2 serology on day 8. Further infectious work-up: Negative respiratory PCR for chlamydophila, mycoplasma, legionella, bordetella, human rhinovirus/enterovirus, Adenovirus, Influenza viruses, RSV, Parainfluenza virus, coronavirus, and MERS-CoV. Positive IgG serology for Mycoplasma pneumoniae, Chlamydophila pneumoniae Negative HIV-test. Negative blood cultures. Negative interferon-gamma release assay. Sputum negative for mycobacteria. | SARS-CoV-2: Negative pharyngeal swab SARS-CoV-2 PCR on admission Negative HIV-test. Negative blood cultures. Negative interferon-gamma release assay. Sputum negative for mycobacteria. |
Further results | WES insignificant, no hypersensitivities in allergy panel; no cold-agglutinin antibodies, Coombs tests negative; slightly increased anti-CCP antibody (10.4 U/mL), otherwise insignificant rheumatologic results; insignificant immunological work-up. | Decreased IgG level (597 mg/dL), no IgG-subclass-irregularities. No WES performed. Inborn anisocoria (right > left), telangiectasia in pons and epidermoid cyst in cerebellopontine angle. | / | / |
Outpatient treatment | Azithromycin, cefuroxime, 1× methylprednisolone burst (8 mg/kg for 3 days), inhaled formoterol/beclometason | Azithromycin, cefuroxime, 10× methylprednisolone burst (10 mg/kg for 3 days), inhaled tobramycin, salmeterol/fluticasone | Cefpodoxim, prednisolone (6 mg/kg for 3 days), inhaled salbutamol, ipratropiumbromid, budesonid | none |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Raedler, J.; Hoelz, H.; Zschocke, A.; Loeffler-Ragg, J.; Paolini, M.; Ley-Zaporozhan, J.; Griese, M. Do Not Miss Acute Diffuse Panbronchiolitis for Tree-in-Bud: Case Series of a Rare Lung Disease. Diagnostics 2022, 12, 1653. https://doi.org/10.3390/diagnostics12071653
Raedler J, Hoelz H, Zschocke A, Loeffler-Ragg J, Paolini M, Ley-Zaporozhan J, Griese M. Do Not Miss Acute Diffuse Panbronchiolitis for Tree-in-Bud: Case Series of a Rare Lung Disease. Diagnostics. 2022; 12(7):1653. https://doi.org/10.3390/diagnostics12071653
Chicago/Turabian StyleRaedler, Johannes, Hannes Hoelz, Anna Zschocke, Judith Loeffler-Ragg, Marco Paolini, Julia Ley-Zaporozhan, and Matthias Griese. 2022. "Do Not Miss Acute Diffuse Panbronchiolitis for Tree-in-Bud: Case Series of a Rare Lung Disease" Diagnostics 12, no. 7: 1653. https://doi.org/10.3390/diagnostics12071653
APA StyleRaedler, J., Hoelz, H., Zschocke, A., Loeffler-Ragg, J., Paolini, M., Ley-Zaporozhan, J., & Griese, M. (2022). Do Not Miss Acute Diffuse Panbronchiolitis for Tree-in-Bud: Case Series of a Rare Lung Disease. Diagnostics, 12(7), 1653. https://doi.org/10.3390/diagnostics12071653